Tackling liver injury

August 11, 2014
This image shows liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left. Credit: Marshall et al., 2014

A new drug spurs liver regeneration after surgery, according to a paper published in The Journal of Experimental Medicine.

Liver cancer often results in a loss of blood flow and thus oxygen and nutrients to the , resulting in deteriorating . Although the diseased part of the liver can often be surgically removed, the sudden restoration of blood flow to the remaining liver tissue can trigger inflammation—a process known as ischemia reperfusion injury (IRI). IRI results in part from the deposition of immune proteins called complement on the surface of , causing them to die and thus impairing liver regeneration.

Complement inhibitors effectively dampen IRI, but the benefits of this approach come at a cost, as certain complement proteins are also required for liver tissue to regrow. A group of scientists at the Medical University of South Carolina now show that a novel complement inhibitor reduces complement-mediated liver cell death and actually stimulates post-surgery liver regrowth in mice. The novel inhibitor limited the deposition of complement proteins and promoted the division of new liver cells. Even after removal of as much as 90% of the liver, treatment increased survival from 0% in untreated animals to an impressive 70%.

The selectivity of this novel complement inhibitor, and its unexpected ability to promote , suggests that it might represent a new treatment strategy for a variety of liver injuries in humans.

Explore further: Restoring what's lost: Uncovering how liver tissue regenerates

More information: Marshall, K.M., et al. 2014. J. Exp. Med. DOI: 10.1084/jem.20131902

Related Stories

Gene mutation may lead to treatment for liver cancer

July 8, 2014

Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature.

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.